LONDON (Reuters) - Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.
via Reuters: Health News Read More Here..
No comments:
Post a Comment